Breaking News Instant updates and real-time market news.

ABT

Abbott

$41.17

0.58 (1.43%)

07:49
10/19/16
10/19
07:49
10/19/16
07:49

Abbott forecasts net specified items for FY16 of approximately $1.60 per share

Abbott forecasts net specified items for the full year 2016 of approximately $1.60 per share. Specified items include intangible amortization expense, the impact of the Venezuelan currency devaluation in the first quarter and an adjustment to the equity investment in Mylan in the third quarter, expenses associated with acquisitions, including bridge facility fees, charges related to cost reduction initiatives and other expenses and the recognition of deferred taxes associated with the pending sale of the Abbott Medical Optics business, partially offset by the favorable resolution of various tax positions from prior years.

  • 19

    Oct

  • 21

    Oct

  • 06

    Nov

ABT Abbott
$41.17

0.58 (1.43%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.

TODAY'S FREE FLY STORIES

ACRS

Aclaris Therapeutics

$28.97

-0.83 (-2.79%)

, NTLA

Intellia Therapeutics

$15.38

0.06 (0.39%)

08:30
12/09/16
12/09
08:30
12/09/16
08:30
Options
Two new option listings and three option delistings on December 9th »

New option listings for…

ACRS

Aclaris Therapeutics

$28.97

-0.83 (-2.79%)

NTLA

Intellia Therapeutics

$15.38

0.06 (0.39%)

LGF

Lionsgate

$26.09

1.1 (4.40%)

LNKD

LinkedIn

STRZA

Starz

$35.52

0.59 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$12.33

-0.3 (-2.38%)

08:30
12/09/16
12/09
08:30
12/09/16
08:30
Conference/Events
Pure Storage participates in a conference call with UBS »

UBS IT Hardware & EMS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 12

    Jan

  • 13

    Jan

  • 09

    Dec

08:30
12/09/16
12/09
08:30
12/09/16
08:30
General news
U.S. equities are back in the green »

U.S. equities are back in…

SGYP

Synergy Pharmaceuticals

$5.54

0.06 (1.09%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Hot Stocks
Breaking Hot Stocks news story on Synergy Pharmaceuticals »

Synergy Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

LFUS

Littelfuse

$154.58

3.1 (2.05%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Conference/Events
Littelfuse to host analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WWD

Woodward

$70.84

-0.26 (-0.37%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Conference/Events
Wayfair Woodward to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DVAX

Dynavax

$4.80

-0.2 (-4.00%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Conference/Events
Dynavax to host research and development day »

Cancer Research and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 15

    Dec

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

08:24
12/09/16
12/09
08:24
12/09/16
08:24
Downgrade
Duluth Holdings rating change  »

Duluth Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBAI

Lakeland Bancorp

$19.15

0.3 (1.59%)

08:24
12/09/16
12/09
08:24
12/09/16
08:24
Syndicate
Breaking Syndicate news story on Lakeland Bancorp »

Lakeland Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSD

Clearside Biomedical

$11.53

-2.9 (-20.10%)

08:23
12/09/16
12/09
08:23
12/09/16
08:23
Syndicate
Clearside Biomedical 4M share Secondary priced at $9.00 »

JPMorgan, Cowen and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

BIIB

Biogen

$289.54

4.24 (1.49%)

, LLY

Eli Lilly

$67.19

-0.19 (-0.28%)

08:21
12/09/16
12/09
08:21
12/09/16
08:21
Recommendations
Biogen, Eli Lilly analyst commentary  »

Biogen has positive read…

BIIB

Biogen

$289.54

4.24 (1.49%)

LLY

Eli Lilly

$67.19

-0.19 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

08:20
12/09/16
12/09
08:20
12/09/16
08:20
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

FNSR

Finisar

$34.13

1.89 (5.86%)

08:17
12/09/16
12/09
08:17
12/09/16
08:17
Recommendations
Finisar analyst commentary  »

Finisar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$83.39

0.47 (0.57%)

08:15
12/09/16
12/09
08:15
12/09/16
08:15
Recommendations
Zebra Technologies analyst commentary  »

Zebra Technologies prie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$170.71

2.16 (1.28%)

08:14
12/09/16
12/09
08:14
12/09/16
08:14
Recommendations
Broadcom analyst commentary  »

Broadcom poised for above…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB Pharma

$30.84

-1.11 (-3.47%)

, MYL

Mylan

$36.06

1.56 (4.52%)

08:14
12/09/16
12/09
08:14
12/09/16
08:14
Periodicals
UCB Pharma Vimpat patent 'thrown out' by patent office, Bronte Capital reports »

Argentum…

UCBJY

UCB Pharma

$30.84

-1.11 (-3.47%)

MYL

Mylan

$36.06

1.56 (4.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

HLT

Hilton

$26.24

-0.8 (-2.96%)

08:14
12/09/16
12/09
08:14
12/09/16
08:14
Downgrade
Hilton rating change  »

Hilton downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CDEV

Centennial Resource Development

$18.29

-0.32 (-1.72%)

08:12
12/09/16
12/09
08:12
12/09/16
08:12
Initiation
Centennial Resource Development initiated  »

Centennial Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTEA

Long Island Iced Tea

$4.91

0.2 (4.25%)

08:12
12/09/16
12/09
08:12
12/09/16
08:12
Hot Stocks
Long Island Iced Tea agrees to acquire ALO Juice »

Long Island Iced Tea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCON

Superconductor Technologies

$2.02

-0.13 (-6.05%)

08:11
12/09/16
12/09
08:11
12/09/16
08:11
Syndicate
Superconductor Technologies raises $10.2M in a public offering »

The offering was priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBMG

Cellular Biomedicine

$13.35

0.1 (0.75%)

08:09
12/09/16
12/09
08:09
12/09/16
08:09
Hot Stocks
Cellular Biomedicine announces 3-month interim safety data from AlloJoin trial »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$89.30

5.57 (6.65%)

08:09
12/09/16
12/09
08:09
12/09/16
08:09
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIRG

Airgain

$18.62

-2.13 (-10.27%)

08:08
12/09/16
12/09
08:08
12/09/16
08:08
Syndicate
Airgain 2.35M share Secondary priced at $17.00 »

Cowen, William Blair and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

SMBK

SmartBank

$19.96

0.66 (3.42%)

, ACBI

Atlantic Capital

$17.00

0.5 (3.03%)

08:08
12/09/16
12/09
08:08
12/09/16
08:08
Hot Stocks
SmartBank to acquire branch office and assets of FSG Bank from Atlantic Capital »

SmartFinancial (SMBK),…

SMBK

SmartBank

$19.96

0.66 (3.42%)

ACBI

Atlantic Capital

$17.00

0.5 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.29

0.01 (0.02%)

08:07
12/09/16
12/09
08:07
12/09/16
08:07
Conference/Events
Wells Fargo holds a conference call »

CFO Shrewsberry and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.